NCT02789228View on ClinicalTrials.gov

Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 12, 2016

Primary Completion Date

April 18, 2022

Study Completion Date

December 31, 2025

Conditions
Solid Tumors
Interventions
BIOLOGICAL

Tumor associated antigen lymphocytes (TAA-CTL)

"This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2"

Trial Locations (1)

20010

Children's National Medical Center, Washington D.C.

Sponsors
All Listed Sponsors
lead

Children's National Research Institute

OTHER